SHANG.FOS.PHARM.GR.H YC 1 Total Liabilities

Latest as of March 2026: €59.30 Billion EUR ≈ $69.32 Billion USD

SHANG.FOS.PHARM.GR.H YC 1 total liabilities. Based on the latest financial reports, SHANG.FOS.PHARM.GR.H YC 1 (08HH) has total liabilities worth €59.30 Billion EUR (≈ $69.32 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are SHANG.FOS.PHARM.GR.H YC 1's assets to evaluate the company's liquid asset resilience ratio.

Total Liabilities of SHANG.FOS.PHARM.GR.H YC 1 (2021–2025)

Total liabilities of SHANG.FOS.PHARM.GR.H YC 1 from 2021 to 2025. This chart illustrates how SHANG.FOS.PHARM.GR.H YC 1's total liabilities have evolved over time, based on quarterly financial data.

SHANG.FOS.PHARM.GR.H YC 1 Competitors by Total Liabilities

The table below lists competitors of SHANG.FOS.PHARM.GR.H YC 1 ranked by their total liabilities.

Company	Country	Total Liabilities
British American Tobacco PLC LSE:BATS	UK	GBX59.79 Billion
Bangkok Life Assurance Public Company Limited BK:BLA	Thailand	฿270.08 Billion
MIPS AB ST:MIPS	Sweden	Skr745.00 Million
Rapport Therapeutics, Inc. Common Stock NASDAQ:RAPP	USA	$36.06 Million
NAVIGATOR HLDGS LTD F:1NV	Germany	€1.02 Billion
Mitra Adiperkasa Tbk JK:MAPI	Indonesia	Rp14.63 Trillion
VIEL & Cie société anonyme PA:VIL	France	€2.21 Billion
Porch Group Inc NASDAQ:PRCH	USA	$780.27 Million

Liability Composition Analysis (2021–2025)

This chart breaks down SHANG.FOS.PHARM.GR.H YC 1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see SHANG.FOS.PHARM.GR.H YC 1 assets under control.

Liquidity & Leverage Metrics

SHANG.FOS.PHARM.GR.H YC 1 Total Liabilities Ratios Explained

SHANG.FOS.PHARM.GR.H YC 1 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	0.93	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.21	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.48	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how SHANG.FOS.PHARM.GR.H YC 1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for SHANG.FOS.PHARM.GR.H YC 1 (2021–2025)

The table below shows the annual total liabilities of SHANG.FOS.PHARM.GR.H YC 1 from 2021 to 2025.

Year	Total Liabilities	Change
2025-12-31	€58.21 Billion ≈ $68.06 Billion	+1.19%
2024-12-31	€57.53 Billion ≈ $67.25 Billion	+1.18%
2023-12-31	€56.85 Billion ≈ $66.47 Billion	+7.16%
2022-12-31	€53.05 Billion ≈ $62.03 Billion	+18.09%
2021-12-31	€44.93 Billion ≈ $52.52 Billion	--

About SHANG.FOS.PHARM.GR.H YC 1

F:08HH Germany Drug Manufacturers - Specialty & Generic

Market Cap

$1.20 Billion

€1.03 Billion EUR

Market Cap Rank

#7821 Global

#1074 in Germany

Share Price

€1.86

Change (1 day)

+1.89%

52-Week Range

€1.66 - €2.60

All Time High

€4.65